Alginate-liposomal construct for bupivacaine delivery and MSC function regulation

Area of Science:

• Biomedical Engineering
• Cell Therapy
• Pharmacology

Background:

• Mesenchymal stromal cells (MSCs) are promising for treating injuries.
• Local anesthetics (LAs) can harm MSC viability and function.
• Co-administration of MSCs and LAs is common in clinical settings.

Purpose of the Study:

• To evaluate the impact of a sustained-release local anesthetic formulation on MSC secretome.
• To assess the effects of alginate-encapsulated liposomal bupivacaine on key regulatory molecules (IL-6, PGE2, TGF-β1).

Main Methods:

• MSCs were exposed to different bupivacaine formulations (bolus, liposome, engineered construct) under inflammatory conditions.
• Secretion of IL-6, PGE2, and TGF-β1 was measured.
• Bupivacaine release kinetics and molecular mediators were analyzed.

Main Results:

• The engineered construct maintained or enhanced anti-inflammatory PGE2 secretion compared to other formulations.
• TGF-β1 secretion was not increased by the engineered construct.
• Drug delivery method controlled LA concentration and influenced MSC secretome.

Conclusions:

• Alginate-encapsulated LA constructs show potential for anti-inflammatory cell therapy co-administration.
• The delivery method of local anesthetics significantly impacts MSC secretome function.
• This formulation supports the use of MSCs alongside local anesthetics in therapeutic applications.